Circle Pharma, Inc.

Circle Pharma, Inc. company information, Employees & Contact Information

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. We recently raised Series B and Series C financing from The Column Group and NextTech Invest. We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). We have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Our workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. We deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.

Company Details

Employees
74
Founded
-
Address
681 Gateway Blvd,
Phone
650-392-0363
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Circle Pharma, Inc. employee's phone or email?

Circle Pharma, Inc. Questions

News

Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire

Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire

Circle Pharma Announces Agreement with Lilly to Further Enhance AI/ML Capabilities and Accelerate Development of New Oral Macrocycle Therapies - Business Wire

Circle Pharma Announces Agreement with Lilly to Further Enhance AI/ML Capabilities and Accelerate Development of New Oral Macrocycle Therapies Business Wire

Circle Pharma to Participate in Upcoming Investor Conferences - Business Wire

Circle Pharma to Participate in Upcoming Investor Conferences Business Wire

Revving up macrocycles, Circle Pharma rides into new, larger space - The Business Journals

Revving up macrocycles, Circle Pharma rides into new, larger space The Business Journals

Wilson Sonsini Advises Circle Pharma on $90 Million Series D - Wilson Sonsini

Wilson Sonsini Advises Circle Pharma on $90 Million Series D Wilson Sonsini

Circle Pharma raises $54M as part of Series D while macrocycles heat up - Endpoints News

Circle Pharma raises $54M as part of Series D while macrocycles heat up Endpoints News

Bucking Biotech's Downward Trend, Circle Pharma Heads To Larger Space - Bisnow

Bucking Biotech's Downward Trend, Circle Pharma Heads To Larger Space Bisnow

FDA Grants Orphan Drug Designation to CID-078 for SCLC - OncLive

FDA Grants Orphan Drug Designation to CID-078 for SCLC OncLive

Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer - Business Wire

Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer Business Wire

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out Seeking Alpha

Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development - FinancialContent

Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development FinancialContent

Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition - Business Wire

Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition Business Wire

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors - Business Wire

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors Business Wire

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting - Business Wire

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting Business Wire

Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies - Business Wire

Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies Business Wire

Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer - Business Wire

Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer Business Wire

Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors - Business Wire

Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors Business Wire

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium - Business Wire

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium Business Wire

Eli Lilly and Company (LLY) Stock: Surge on $1B AI-Powered Drug Discovery Platform and Circle Pharma Deal - CoinCentral

Eli Lilly and Company (LLY) Stock: Surge on $1B AI-Powered Drug Discovery Platform and Circle Pharma Deal CoinCentral

Lilly helps Circle round up $66M for intractable target R&D - Fierce Biotech

Lilly helps Circle round up $66M for intractable target R&D Fierce Biotech

Top Circle Pharma, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant